H.C. Wainwright & Co. reaffirmed its Buy rating and $15.00 price target for Emergent BioSolutions stock (NYSE:EBS). The ...

The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...

Shionogi & Co. has been awarded a $375 million project agreement by the Biomedical Advanced Research and Development ...

"$590m to Moderna from HHS for mRNA ‘flu vax development" was originally created and published by Pharmaceutical Technology, ...

Shionogi will receive $375 million to develop a long-acting protease inhibitor designed to prevent SARS-CoV-2 infection in ...

Moderna (MRNA) announced ongoing support from the U.S. Department of Health and Human Services, HHS, to accelerate the development of ...

today announced the company won the Biomedical Advanced Research and Development Authority (BARDA) Patch Forward competition and presented at an event during the J.P. Morgan Healthcare Conference ...

Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The ...

Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, has been named a C ...

proudly announces its selection as a Concept Stage winner in the prestigious United States Biomedical Advanced Research and Development Authority (BARDA) Patch Forward Prize. Achieved in ...

Micron Biomedical, a life science company developing the world’s first needle-free technology for drugs and vaccines that is based on dissolvable microarrays, ...

The award was made through the Rapid Response Partnership Vehicle (RRPV) Consortium with funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS ...